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Activation of MET by Gene Amplification or by Splice
Mutations Deleting the Juxtamembrane Domain in Primary
Resected Lung Cancers
Ryoichi Onozato, MD,*† Takayuki Kosaka, MD,*† Hiroyuki Kuwano, MD,† Yoshitaka Sekido, MD,‡
Yasushi Yatabe, MD,§ and Tetsuya Mitsudomi, MD*
Introduction:MET (Met proto-oncogene) activation either by gene
amplification or mutation is implicated in various types of human
cancers. For lung cancer, MET gene amplification is reported to
occur in a subset of adenocarcinomas. Although somatic mutations
of MET in lung adenocarcinomas are rare, all but one of those
reported so far entail a splice mutation deleting the juxtamembrane
domain for binding the c-Cbl E3-ligase; normally such binding leads
to ubiquitination and receptor degradation, and loss of this domain
leads to MET activation. The purpose of this study was to clarify in
the role of MET activation in lung carcinogenesis.
Materials and Methods: MET gene copy number was determined
by real-time quantitative polymerase chain reaction in 187 of the
patients with lung cancer and the MET gene splice mutation deleting
the juxtamembrane domain was examined by direct sequencing in
262. The results were correlated with various clinical and pathologic
features including mutations of the epidermal growth factor recep-
tor, KRAS, and HER2 genes.
Results: All the instances of MET activation occurred in patients
with adenocarcinomas. The prevalences of MET gene amplification
and splice mutations were 1.4% (2 of 148) and 3.3% (7 of 211),
respectively. We identified four different intronic mutations that
disrupted a splice consensus sequence in genomic DNA. Activation
of MET and mutations of the epidermal growth factor receptor,
KRAS, and HER2 genes had strict mutual exclusionary relationships.
Conclusions: About 5% of pulmonary adenocarcinomas in this
cohort of Japanese patients were driven by activated MET by gene
amplification or splice mutations. Such patients would be candidates
for targeted therapy against MET.
Key Words: MET, Lung cancer, Adenocarcinoma, Somatic muta-
tion, Gene amplification.
(J Thorac Oncol. 2009;4: 5–11)
MET (met proto-oncogene) is a receptor tyrosine kinasethat phosphorylates several tyrosine residues after
binding its specific ligand, hepatocyte growth factor. Recep-
tor phosphorylation activates downstream signals, including
phosphatidyl inositol 3-kinase, mitogen-activated protein ki-
nase, and phospholipase C- and leads to epithelial-mesen-
chymal transition, cell scattering, angiogenesis, proliferation,
enhanced cell motility, invasion, and metastasis.1,2
Accumulating evidence suggests that MET plays an
important role in the pathogenesis of human lung cancer.
Amplification and overexpression of the MET gene (located
at 7q31) is reported to occur in a subset of patients with
pulmonary adenocarcinomas that do not harbor mutation of
the EGFR (epidermal growth factor receptor) gene.3 Lung
and gastric cancer cell lines with MET gene amplification has
been reported to lead to enhanced phosphorylation of the
MET gene.4,5 Furthermore, MET gene amplification could be
detected in about 20% of patients with lung adenocarcinomas
who developed acquired resistance to EGFR TKI.6,7
In Caucasian patients with lung adenocarcinoma, muta-
tions of the MET gene have been reported to occur in 7.1% (9 of
127)8 and 12.1% (4 of 33).9 When confined to somatic muta-
tions, the prevalences have been reported to occur in 1.6% (2 of
127)8 and 6.0% (2 of 33).9 Of these 4 somatic mutations, 3 were
splice mutations that resulted in deletion of exon 14 coding for
the juxtamembrane domain. Another was a point mutation in an
extracellular semaphorin domain (L229F). Mutations in the
kinase domain were not detected in any lung adenocarcinomas
(0 of 160).8,9 On the contrary, all the mutations found in sporadic
papillary-type renal cell carcinomas (17 of 129; 13%), childhood
hepatocellular carcinomas (3 of10; 30%), and head and neck
squamous cell carcinomas (4 of 15; 27%) occurred within the
tyrosine kinase domain.10–13 This fact contrasts strongly with
other types of cancer.
Tyrosine 1003 in the juxtamembrane domain of MET is a
binding site for c-Cbl, an ubiquitin protein ligase (E3), which
causes ubiquitination, receptor endocytosis, and degradation of
MET.14 Therefore, deletion of the juxtamembrane domain (exon
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14) is one mechanism for MET activation, as shown by Kong-
Beltran et al.9 The mutant MET exhibits decreased ubiquitina-
tion and delayed down-regulation correlating with elevated,
distinct MET production.9 Therefore, phospho-MET levels and
downstream mitogen-activated protein kinase activation are sus-
tained following ligand stimulation.9
Because the mutational frequencies of the EGFR or
KRAS genes differ markedly between Japanese and Western
patients, it would be of interest to determine the prevalence of
MET activation by gene amplification or mutation in a
Japanese cohort. Therefore, we decided to search for MET
amplification and for mutations deleting the juxtamembrane
domain, and evaluated their clinicopathological significance
including any associations with EGFR and KRAS mutations.




We studied 262 patients with lung cancer who under-
went potentially curative pulmonary resection at the Depart-
ment of Thoracic Surgery, Aichi Cancer Center Hospital,
from May 2000 through 2002. Tumor samples were frozen
rapidly in liquid nitrogen, after obtaining the appropriate
approval from the Institutional Review Board and the pa-
tients’ written informed consent. All the patients were Japa-
nese; 149 were men and 113 were women, with ages at
diagnosis ranging from 26 to 89 years (median 64 years). One
hundred forty-nine patients had stage I disease, 33 had stage
II, 75 had stage III, and 5 had stage IV. There were 211
adenocarcinomas, 33 squamous cell carcinomas, 6 adeno-
squamous carcinomas, 10 large cell carcinomas, and 2 small
cell carcinomas. One hundred and seven patients had never
smoked and 155 were current or former smokers. We had
previously determined the EGFR, and KRAS mutational sta-
tus in this cohort.15–17
Cell Lines
Twenty-two lung cancer cell lines were available for
this study. These comprised 9 adenocarcinomas, A549, ACC-
LC-319, NCI-H358, NCI-H838, NCI-H1666, NCI-H1993,
NCI-H2009, NCI-H2882, RERF-LC-MT; 5 squamous cell
carcinomas, Calu1, PC-1, PC-10, SK-MES-1 and RERF-LC-
AI; 3 large cell carcinomas, Calu6, NCI-H460 and SK-LC-6;
one non-small cell lung carcinoma (NSCLC), NCI-H1299; 4
small cell carcinomas, ACC-LC-48, ACC-LC-49, ACC-LC-
80, and SK-LC-2. Two gastric cancer cell lines, KATOIII and
MKN45 were also used. NCI-H358, H460, H838, H1299,
H1666, H1993, H2009, and H2882 were gifts from Dr. Adi F.
Gazdar. KATOIII and MKN45 were obtained from the Cell
Resource Center for Biomedical Research Institute of Devel-
opment, Aging and Cancer (Tohoku University, Sendai, Ja-
pan). The derivation of other cell lines has been described
previously.18,19 All cell lines were cultured in RPMI-1640
(Sigma-Aldrich, Irvine, UK) with supplemented with 10%
fetal bovine serum (Invitrogen, Carlsbad, CA) and 1antibi-
otic-antimycotic (Invitrogen) at 37°C in a humidified incuba-
tor with 5% CO2. NCI-H19934,7 and MKN455 cell lines have
amplification of the MET gene, while KATO III does not.5
RNA and DNA Extraction
Frozen tumor tissue sections were grossly dissected by
a surgical pathologist (Y. Y.) to enrich tumor cells as much as
possible. Total RNAs and genomic DNAs contained at least
20% of tumor content in our cohort. Total RNA was isolated
using the RNeasy Kit (Qiagen, Valencia, CA) in 262 cases.
For extraction of genomic DNA, tissues were incubated with
1PCR (polymerase chain reaction) buffer containing 100
g/ml proteinase K for 1 hour at 54°C. Next, the solution was
incubated for 3 minutes at 95°C. Genomic DNA was extracted in
187 unselected patients for whom tumor blocks were available.
Analysis of MET Gene Amplification
The copy number of the MET gene relative to a LINE-1
repetitive element was determined by quantitative real-time
PCR using the SYBR Green Method (QuantiTect SYBR
Green PCR Kit; Qiagen) using an ABI PRISM 7900HT
Sequence Detection System (Applied Biosystems, Foster
city, CA) according to Engelman et al.7 The copy number of
the LINE-1 is reported to be similar between normal and
cancerous cells.20 The standard curve method was used to
calculate MET gene copy number in the cell line or tumor
DNA sample relative to the Line-1 repetitive element.20
Quantification was based on standard curves from a serial
dilution of Calu6 genomic DNA. Calu6 was selected as a
standard sample, because amount of MET gene relation to
Line-1 was almost 1.00. Primer sequences for the MET gene
were 5-TAGAAGAGCCCAGCCAGTGT-3 (forward), 5-
CGAATGCAATGGATGATCTG-3 (reverse), and for
LINE-1 were 5-AAAGCCGCTCAACTACATGG-3 (for-
ward), 5-TGCTTTGAATGCGTCCCAGAG-3(reverse).
All the specimens were analyzed in triplicate using 20 ng of
genomic DNA. We defined that amplification was present
when the copy number was two or more.
Analysis of the Splice Mutation of the MET
Gene Around the Juxtamembrane Domain
The cDNA sequence of the MET gene was obtained
from GenBank (accession number NM 000245.2). The exon
14 that codes for the juxtamembrane domain of the MET gene
was amplified with primer F (5-TGAAATTGAACAGC-
GAGCTAAAT-3) and R (5- TTGAAATGCACAATCAG-
GCTAC-3), in an one-step reverse transcription (RT)-PCR
setup with Qiagen OneStep Reverse Transcription-PCR kits
(Qiagen) using 4 ng of total RNA. The conditions for RT-
PCR were one cycle of 50°C for 30 minutes, 95°C for 15
minutes, 45 cycles of 94°C for 40 seconds, 62°C for 40
seconds, 72°C for 1 minute, and one cycle of 72°C for 10
minutes. After RT-PCR, free nucleotides and excess primer
were removed using PCR Purification kit (QIAGEN). PCR
products were diluted and cycle sequenced using the BigDye
Terminator Cycle Sequencing Kit v. 3.1/1.1 (Applied Bio-
systems). Sequencing reaction products were separated elec-
trophoretically on an ABI PRISM 3100 apparatus (Applied
Biosystems). Both the forward and reverse sequences ob-
tained were analyzed with BLAST and by manual review.
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For cases with MET mutations identified by sequencing
of the RT-PCR product, we also analyzed 100 ng aliquots of
genomic DNA to examine the mechanism for alternative
splicing. The genomic DNA sequence of the MET gene was
obtained from GenBank (accession number NC 000007.12).
PCR of genomic DNA was carried out using AmpliTaq Gold
(Applied Biosystems) for introns 13 and 14. PCR primers
(encompassing from the 5 splice site of intron 13 to the 5
splice site of intron 14; nucleotide numbers of genomic DNA
from 99615 to 99728) were as follows: 5-GATTGCTGGTGT-
TGTCTCAATATC-3 (forward) and 5-TGTCAAATACT-
TACTTGGCAGAGG-3 (reverse). The PCR condition was:
one cycle of 95°C for 10 minutes, 40 cycles of 94°C for 30
seconds, 62°C for 30 seconds, 72°C for 40 seconds, and one
cycle of 72°C for 10 minutes. Sequence analysis was carried out
as for the RNA analysis.
Analysis of the HER2 Gene Mutation
We sequenced exon 20 of the tyrosine kinase domain of
the HER2 gene where all the mutations are reported.21–23 The
cDNA sequence of the HER2 gene was obtained from Gen-
Bank (accession number NM 004448). Primer sequences
were 5-ACAGTCTACAAGGGCATCTGGA-3 (forward),
and 5-AACTCCACACATCACTCTGGTG-3 (reverse).
The RT-PCR conditions were one cycle of 50°C for 30
minutes, 95°C for 15 minutes, 40 cycles of 94°C for 40
seconds, 62°C for 40 seconds, 72°C for 1 minute, and one
cycle of 72°C for 10 minutes.
Statistical Analysis
The 2 test was used to compare proportions. The
two-sided significance level was set at p  0.05. All analyses
were carried out using StatView software (version 5; SAS
Institute, Cary, NC).
RESULTS
MET Gene Amplification in Lung Cancer
Specimens
First, we searched for amplification of the MET gene
in 22 lung cancer cell lines and 2 gastric cancer cell lines
(Figure 1). MET amplifications were detected in the ACC-
LC-319 adenocarcinoma cell line. Two of the cell lines
(NCI-H1993, lung cancer and MKN45, gastric cancer)
have been reported to harbor MET gene amplifications4,5,7
and we confirmed this findings. Relative copy numbers of
the MET gene for the ACC-LC-319, NCI-H1993, and
MKN-45 cell lines were 7.26, 5.22, and 8.43, respectively.
In 187 clinical specimens (148 adenocarcinomas, 28
squamous carcinomas, 4 adenosquamous carcinomas, 6 large
cell carcinomas, and 1 small cell carcinoma), we detected
only 2 MET gene amplifications (Figure 1). The MET copy
numbers of these 2 patients were 6.72 (T1095) and 2.43
(T1323). The prevalence of MET gene amplification in ade-
nocarcinomas was thus 1.4% (2 of 148).
MET Gene Splice Mutations Deleting the
Juxtamembrane Domain
We searched for splice mutations of the MET gene
deleting the juxtamembrane domain using 22 lung cancer
cell lines, however, mutation was not detected. Next, we
performed mutational search in a cohort of 262 lung
cancers that included those examined for gene amplifica-
tion. We identified 7 MET mutations in 262 lung cancer
specimens (2.7%; Table 1, Figure 2A). All 7 mutations
were confirmed by a second independent PCR. All the
mutations were deletions of nucleotides 3075 to 3215
(according to NM 000245.2) corresponding with the se-
quence of exon 14. This would result in a 47 amino-acid
FIGURE 1. Relative copy number
of the MET gene determined by re-
al-time quantitative PCR (polymer-
ase chain reaction) in 24 cell lines
and 187 lung cancer specimens.
MKN45 and NCI-H1993 cell lines
showing MET amplification served
as positive controls. Solid triangles
indicate samples that had MET
splice mutations in the following
experiments.
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deletion of the exon 14 (L964 through D1010 in the
juxtamembrane domain), identical with that reported.8,9
RNAs from matched tumor and normal lung tissues
were available for 5 patients with MET mutations (except
T1021 and T1065). Deletion of exon 14 was only present in
tumor samples by RT-PCR and sequencing experiments in-
dicated that this was a somatic event (Figure 2B). In addition,
we noticed that bands for the mutant allele (shorter) were
always stronger than bands for the wild type allele (Figure
2B). In 3 tumors (patients T1181, T1307, and T1384), bands
for the wild type allele were almost invisible. However, none
of seven tumors with MET mutations harbored MET ampli-
fication in the preceding experiments.
Mechanisms for the Deletion of Exon 14 of the
MET Gene
To investigate the mechanism for the deletion of
exon 14 of the MET gene in cDNA, we sequenced introns
13 and14 for any sequencing alterations, using genomic
DNA. We identified four intronic mutations that would
affect RNA splicing by disrupting consensus sequenc-
es.24,25 Patient T1021 had a point mutation at the 5 splice
site of intron 14. Patients T1148, T1165, T1307 had
deletions either involving the 3 splice site, a branch site,
or the polypyrimidine tract of intron 13 (Figure 3A, B),
respectively.24 Contrary to the cDNA sequencing, these
FIGURE 2. A, Examples of cDNA sequencing
chromatograms of the MET gene. In patient
T1021, exon 13 was spliced directly to exon 15,
skipping exon 14. The chromatogram for the wild
type sequence is shown in the upper panel for
comparison. Red characters represent a splice mu-
tation. Red arrows indicate the primer position for
reverse transcription-polymerase chain reaction
(RT-PCR). B, Agarose gel electrophoresis of the
RT-PCR product encompassing exon 14 of the
MET gene of the paired tumor and normal sam-
ples. T, tumor; N, normal lung tissue; N.C, nega-
tive control; P.C, positive control. The difference
between the larger and smaller bands appears to
correspond with length of the exon 14 (141 bp).
TABLE 1. Clinicopathological Features of the Patients with the MET Amplification or Splice Mutation in Lung Cancer Patients
Patient Number Age Sex Histology (differentiation) Stage Smoking Status Prognosis (d)
Amplification T1095 64 Male AD(M) IB S 1094:DOD
T1323 71 Male AD (P) IB S 516:DOD
Mutation T1021 62 Male AD (P) IA S 2732:NED
T1148 74 Female AD(M) IB NS 2029:NED
T1165 76 Male AD(M) IA S 1611:DOD
T1181 67 Male AD(W) IA S 1953:NED
T1241 60 Female AD(M) IIB NS 2241:NED
T1307 75 Male AD (P) IB S 2101:NED
T1384 56 Female AD(M) IA NS 1872:NED
AD, adenocarcinoma; M, moderately differentiated; P, poorly differentiated; W, well differentiated; S, smoker; N, never-smoker; DOD, dead of disease; NED, no evidence of
disease.
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mutations were heterozygous (Figure 3A). Matched normal
lung of these four patients had wild-type sequences (data
not shown).
HER2 Mutation in Lung Cancers
We identified 6 HER2 mutations in the 262 lung
cancer specimens (2.3%). Five mutations were a 12-bp
duplication/insertion of the amino acids YVMA at codon
776 and one mutation was a 9-bp insertion of the amino
acids VGS at codon 779. All patients with the HER2
mutation, except for one with an adenosquamous carci-
noma, had adenocarcinomas. Five patients were women
and one was a man. Four patients had stage IA tumors, one
had stage IB, and one had stage IIIA. Four patients were
never smokers and two were smokers.
Relationships Between Patients with MET Gene
Amplification or Splice Mutation and
Clinicopathological Backgrounds Indicating
Mutations of the EGFR, KRAS, and HER2 Genes
Table 1 shows the clinicopathological backgrounds for
9 patients with MET gene amplification or splice mutation.
All the patients had adenocarcinomas. Two patients with
amplification were male smokers. Four patients with the MET
mutation were male smokers and three were female never-
smokers. All except for T1241 had stage I tumors. There were
no significant differences among clinicopathological factors
according to MET mutation status (Table 2).
EGFR, KRAS, and HER2 mutations were identified in
103 (48.8%), 29 (13.7%), and 5 (2.4%) of 211 lung adeno-
carcinomas, respectively, and these 3 mutations were mutu-
ally exclusionary as reported.15,26 MET gene activation by
FIGURE 3. A, Sequencing chromatograms of genomic DNA with intronic mutation of the MET gene: Red characters repre-
sent deletions or point mutations in genomic DNA. Four intronic mutations were detected in this analysis. B, Diagrammatic
representations of the mechanisms for eliminating exon 14 of the MET gene: (i) The 5 splice site, 3 splice site, branch site,
and polypyrimidine tract are indicated as consensus motifs at the top of figure.24,25,28 Blue arrows indicated primers for poly-
merase chain reaction (PCR). (ii) Diagrammatic representations of Figure 3A. (iii) Three intronic mutations reported previously
by Kong-Beltran et al.9 All intronic mutations detected in this analysis were different from those reported.9 Each mutation is
indicated by a red arrow. Py, pyrimidine.
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amplification or mutation occurred selectively in these ade-
nocarcinomas without EGFR, KRAS or HER2 mutations with
a statistical significance (p  0.0001; Figure 4).
DISCUSSION
We found that about 5% of lung adenocarcinomas had
MET activation either by gene amplification (2 of 148 pa-
tients, 1.4%) or splice mutations deleting the juxtamembrane
domain (7 of 211 patients, 3.3%). Unlike EGFR or HER2
mutations that mainly target female, Asian and nonsmoking
patients, and unlike KRAS mutations that mainly target male,
Caucasian and smoking patients,15–17,21,26 there was no such
relationship for MET activation.
MET gene amplification was detected in 22% (4 of 18)
of NSCLCs that had developed acquired resistance to EGFR
tyrosine kinase inhibitors (TKIs).7 The prevalence of MET
amplification in primary lung cancer patients unexposed to
such inhibitors had not been elucidated until recently. How-
ever, Bean et al.6 reported that MET amplification was present
only in 2 of 62 EGFR-TKI-untreated patients, but that it was
present in 9 of 43 patients with acquired resistance. This is in
agreement with our results, suggesting that there is no ethnic
difference in this clinical feature and that gene amplification
does not play a major role for development of pulmonary
adenocarcinomas without EGFR-TKI treatment.
There was also no significant difference in the preva-
lence of MET somatic mutation between our study (7 of 211,
3.3%) and previous studies from Western countries (2 of 127,
1.6%8 or 2 of 33, 6%9). We were able to identify cis-acting
intronic mutations of the MET gene that disrupted splice
consensus sequence in four of seven patients. However, in the
remaining three patients, the mechanisms for abnormal splic-
ing could not be determined. Other possible mechanisms
included mutations and nongenetic alterations of factors re-
quired for constitutive or alternative splicing or formation of
the fusion proteins involving splice factors resulting from
cancer-associated chromosomal translocations.24 Interest-
ingly, mechanisms leading to deletion of exon 14 in 7 cases
including those reported by Kong-Beltran et al. (Figure 3B)
were all different. This also suggest the notion that deletion of
exon 14 plays an important role in the development of lung
adenocarcinomas, conferring various advantages to the tumor
cells and that MET splice mutations are ‘‘driver mutations’’
and not just ‘‘passenger mutations.’’27
Although a MET splice mutation did not occur in tumors
with MET amplification, we noticed that mutant alleles were
transcribed preferentially in RT-PCR or sequencing experi-
ments. Kong-Beltran et al.9 reported similarly that the deleted
form of the MET receptor is expressed predominantly despite
their tumor samples being heterozygous for exon 14, suggesting
preferential expression of the variant transcript.
Shibata et al.3 reported that MET amplification occur in
tumors without EGFR mutations. Kong-Beltran et al.9 found
that tumors harboring these intronic mutations were wild type
for KRAS, BRAF, EGFR, and HER2. In the present study, we
were able to confirm and extend these findings. MET activa-
tion by amplification or splice mutation was present only in
tumors without any mutations of the EGFR, KRAS, or HER2
TABLE 2. Characteristic Clinicopathological Factors
According to MET Mutation Status in 211 Patients with Lung
Adenocarcinomas






Male 4 (57%) 98 (48%) 0.714 0.552
Female 3 (43%) 106 (52%)
Age
64 2 (29%) 104 (51%) 0.279 0.736
64 5 (71%) 100 (49%)
Stage
– 7 (100%) 140 (69%) 0.104 0.981
–V 0 (0%) 64 (31%)
Smoking status
Never-smoker 3 (43%) 102 (50%) 0.999 0.644
Smoker 4 (57%) 102 (50%)
Differentiation
W-M 5 (71%) 139 (68%) 0.999 0.365
P 2 (29%) 65 (32%)
EGFR
Mutated 0 (0%) 103 (50%) 0.014 0.976
Wild type 7 (100%) 101 (50%)
KRAS
Mutated 0 (0%) 29 (14%) 0.597 0.987
Wild type 7 (100%) 175 (86%)
HER2
Mutated 0 (0%) 5 (2%) 0.999 0.995
Wild type 7 (100%) 199 (98%)
M, moderately differentiated; P, poorly differentiated; W, well differentiated;
EGFR, epidermal growth factor receptor.
FIGURE 4. Frequencies of MET activation by gene amplifi-
cation or splice mutation and the mutations of each gene in
211 Japanese patients with lung adenocarcinomas. Thirty
percent of the specimens had no mutations of the epidermal
growth factor receptor (EGFR), KRAS or HER2 genes and did
not show MET activation. Each instance of MET activation
detected in this series was mutually exclusionary with these
gene mutations. FGFR4 mutation and EML4-ALK fusion gene
have been reported to occur in similar exclusionary fashion
and be present in 1 of 158 (0.6%) and 5 of 149 (3.4%) of
lung adenocarcinomas, respectively, these may be encom-
passed in the part of Unknown.29,30
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genes. This again suggests that MET activation plays an
important role that is equivalent to mutations of the EGFR,
KRAS or HER2 genes. Altogether, lung adenocarcinomas
containing the MET activation seem to form a novel and
independent subclass of such tumors.
In the present study, 30% of Japanese patients with
adenocarcinomas of lung did not harbor any mutations of
EGFR, KRAS or HER2 and MET activation by gene ampli-
fications or splice mutations (Figure 4). To generate a thera-
peutic strategy for these patients, it will be important to
discover activated genes that have complementary roles.
Tumor cell lines with activated MET either by gene
amplification or splice mutations are highly sensitive to MET
targeted therapy.4,5,9 A dramatic reduction in tumor cell
numbers was observed using the MET TKI, PHA665752, in
gastric cancer cell lines with a MET amplification including
the MKN45 cells used in the present study.5 Short hairpin
RNA-mediated MET knockdown induced significant growth
inhibition, G1/S cell cycle arrest, and apoptosis in EBC-1 and
H1993 cells showing MET amplification, whereas it had little
or no effect on cell lines not exhibiting MET amplification.4
Similarly, a lung cancer cell line (NCI-H596) harboring a
splice variant of MET was sensitive to an anti-MET OA-5D5
antibody.9 Altogether, these results strongly suggest that
MET activation identifies a subset of NSCLCs that is likely to
respond to new molecular therapies targeting MET.
In conclusion, we found that about 5% of pulmonary
adenocarcinomas were driven by activated MET by gene am-
plifications or splice mutations. Although this prevalence seems
low, a considerable number of patients with lung cancers would
benefit from anti-MET strategy, considering that over one mil-
lion deaths are caused by lung cancer worldwide annually.
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